Zhang Q, Han J, Zhu Y, Yu F, Hu X, Tong H
J Comput Aided Mol Des. 2023; 37(12):695-706.
PMID: 37642861
DOI: 10.1007/s10822-023-00530-4.
Liu M, Dyson P
Nat Commun. 2023; 14(1):2830.
PMID: 37217549
PMC: 10203214.
DOI: 10.1038/s41467-023-38534-1.
Bieri C, Esmel A, Keita M, Owono L, Dali B, Megnassan E
Int J Mol Sci. 2023; 24(8).
PMID: 37108083
PMC: 10139228.
DOI: 10.3390/ijms24086916.
Ibrahim T, Taher E, Samir E, Malebari A, Khayyat A, Mohamed M
Molecules. 2020; 25(14).
PMID: 32650556
PMC: 7397076.
DOI: 10.3390/molecules25143125.
Konstantinovic J, Videnovic M, Srbljanovic J, Djurkovic-Djakovic O, Bogojevic K, Sciotti R
Molecules. 2017; 22(3).
PMID: 28245583
PMC: 6155332.
DOI: 10.3390/molecules22030343.
Rationalizing the Binding Kinetics for the Inhibition of the Burkholderia pseudomallei FabI1 Enoyl-ACP Reductase.
Neckles C, Eltschkner S, Cummings J, Hirschbeck M, Daryaee F, Bommineni G
Biochemistry. 2017; 56(13):1865-1878.
PMID: 28225601
PMC: 5401771.
DOI: 10.1021/acs.biochem.6b01048.
Modification of triclosan scaffold in search of improved inhibitors for enoyl-acyl carrier protein (ACP) reductase in Toxoplasma gondii.
Stec J, Fomovska A, Afanador G, Muench S, Zhou Y, Lai B
ChemMedChem. 2013; 8(7):1138-60.
PMID: 23776166
PMC: 3755765.
DOI: 10.1002/cmdc.201300050.
Development of a triclosan scaffold which allows for adaptations on both the A- and B-ring for transport peptides.
Muench S, Stec J, Zhou Y, Afanador G, McPhillie M, Hickman M
Bioorg Med Chem Lett. 2013; 23(12):3551-5.
PMID: 23664871
PMC: 3683578.
DOI: 10.1016/j.bmcl.2013.04.035.
Structural and enzymatic analyses reveal the binding mode of a novel series of Francisella tularensis enoyl reductase (FabI) inhibitors.
Mehboob S, Hevener K, Truong K, Boci T, Santarsiero B, Johnson M
J Med Chem. 2012; 55(12):5933-41.
PMID: 22642319
PMC: 3386789.
DOI: 10.1021/jm300489v.
Structure of the Yersinia pestis FabV enoyl-ACP reductase and its interaction with two 2-pyridone inhibitors.
Hirschbeck M, Kuper J, Lu H, Liu N, Neckles C, Shah S
Structure. 2012; 20(1):89-100.
PMID: 22244758
PMC: 3361726.
DOI: 10.1016/j.str.2011.07.019.
Targeting the Lipid Metabolic Pathways for the Treatment of Malaria.
Ben Mamoun C, Prigge S, Vial H
Drug Dev Res. 2010; 71(1):44-55.
PMID: 20559451
PMC: 2886290.
DOI: 10.1002/ddr.20347.
Molecular modeling studies, synthesis, and biological evaluation of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR) inhibitors.
Morde V, Shaikh M, Pissurlenkar R, Coutinho E
Mol Divers. 2009; 13(4):501-17.
PMID: 19347595
DOI: 10.1007/s11030-009-9141-0.
Design and synthesis of aryl ether inhibitors of the Bacillus anthracis enoyl-ACP reductase.
Tipparaju S, Mulhearn D, Klein G, Chen Y, Tapadar S, Bishop M
ChemMedChem. 2008; 3(8):1250-68.
PMID: 18663709
PMC: 2693028.
DOI: 10.1002/cmdc.200800047.
Make it or take it: fatty acid metabolism of apicomplexan parasites.
Mazumdar J, Striepen B
Eukaryot Cell. 2007; 6(10):1727-35.
PMID: 17715365
PMC: 2043401.
DOI: 10.1128/EC.00255-07.
Mass spectrometry-based systems approach for identification of inhibitors of Plasmodium falciparum fatty acid synthase.
Sharma S, Sharma S, Modak R, Karmodiya K, Surolia N, Surolia A
Antimicrob Agents Chemother. 2007; 51(7):2552-8.
PMID: 17485508
PMC: 1913259.
DOI: 10.1128/AAC.00124-07.
Studies of Toxoplasma gondii and Plasmodium falciparum enoyl acyl carrier protein reductase and implications for the development of antiparasitic agents.
Muench S, Prigge S, McLeod R, Rafferty J, Kirisits M, Roberts C
Acta Crystallogr D Biol Crystallogr. 2007; 63(Pt 3):328-38.
PMID: 17327670
PMC: 2483495.
DOI: 10.1107/S0907444906053625.